These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34187401)

  • 1. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
    BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
    Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
    Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
    Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
    Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
    Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
    Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
    Panayiotidis P; Follows GA; Mollica L; Nagler A; Özcan M; Santoro A; Stevens D; Trevarthen D; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL; Dreyling M
    Blood Adv; 2021 Feb; 5(3):823-828. PubMed ID: 33560394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
    Eltantawy A; Vallejos X; Sebea E; Evans K
    Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenalidomide plus rituximab (R
    Becnel MR; Nastoupil LJ; Samaniego F; Davis RE; You MJ; Green M; Hagemeister FB; Fanale MA; Fayad LE; Westin JR; Wang M; Oki Y; Forbes SG; Feng L; Neelapu SS; Fowler NH
    Br J Haematol; 2019 Jun; 185(5):874-882. PubMed ID: 30919940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
    Munoz J; Follows GA; Nastoupil LJ
    Target Oncol; 2021 May; 16(3):295-308. PubMed ID: 33687623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Gordon MJ; Feng L; Strati P; Lee HJ; Hagemeister FB; Westin JR; Samaniego F; Marques-Piubelli ML; Vega Vazquez F; Parra Cuentas ER; Solis-Soto LM; Ma W; Wang J; Claret L; Averill B; Ibanez K; Fayad LE; Flowers CR; Green MR; Davis RE; Neelapu SS; Fowler NH; Nastoupil LJ
    Cancer; 2024 Mar; 130(6):876-885. PubMed ID: 37985359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Marret G; Isambert N; Rezai K; Gal J; Saada-Bouzid E; Rolland F; Chausson M; Borcoman E; Alt M; Klijanienko J; Vansteene D; Guigay J; Kamal M; Bièche I; Le Tourneau C;
    Invest New Drugs; 2021 Dec; 39(6):1641-1648. PubMed ID: 34322775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copanlisib: First Global Approval.
    Markham A
    Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marginal Zone Lymphoma: State-of-the-Art Treatment.
    Sindel A; Al-Juhaishi T; Yazbeck V
    Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.
    Vannata B; Vanazzi A; Negri M; Liptrott SJ; Bartosek AA; Miani M; Di Sanzo A; Cavalli F; Zucca E; Stathis A
    Hematol Oncol; 2021 Feb; 39(1):60-65. PubMed ID: 33103778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TF; Muche R; Dreyhaupt J; Buske C
    Future Oncol; 2020 May; 16(13):817-825. PubMed ID: 32223334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
    Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
    Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
    J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.